Education
About Us
Working with TipRanks
Follow Us
Whitehawk Therapeutics (WHWK)
NASDAQ:WHWK
Total Valuation
Whitehawk Therapeutics has a market cap or net worth of $85.30M. The enterprise value is -$48.01M.
Market Cap$85.30M
Enterprise Value-$48.01M
Share Statistics
Whitehawk Therapeutics has 47,128,360 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding47,128,360
Owned by Insiders26.29%
Owned by Institutions4.96%
Financial Efficiency
Whitehawk Therapeutics’s return on equity (ROE) is -1.21 and return on invested capital (ROIC) is -126.06%.
Return on Equity (ROE)-1.21
Return on Assets (ROA)-0.91
Return on Invested Capital (ROIC)-126.06%
Return on Capital Employed (ROCE)-1.27
Revenue Per Employee649.58K
Profits Per Employee-1.59M
Employee Count40
Asset Turnover0.37
Inventory Turnover10.18
Valuation Ratios
The current PE Ratio of Whitehawk Therapeutics is 12.0. Whitehawk Therapeutics’s PEG ratio is ―.
PE Ratio12.0
PS Ratio―
PB Ratio―
Price to Fair Value1.63
Price to FCF―
Price to Operating Cash Flow-1.24
PEG Ratio―
Income Statement
In the last 12 months, Whitehawk Therapeutics had revenue of 25.98M and earned -63.69M in profits. Earnings per share was -2.36.
Revenue25.98M
Gross Profit-28.07M
Operating Income-67.46M
Pretax Income-63.69M
Net Income-63.69M
EBITDA-64.63M
Earnings Per Share (EPS)-2.36
Cash Flow
In the last 12 months, operating cash flow was -95.56M and capital expenditures -926.00K, giving a free cash flow of -96.49M billion.
Operating Cash Flow-95.56M
Free Cash Flow-96.49M
Free Cash Flow per Share-2.05
Dividends & Yields
Whitehawk Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.49
52-Week Price Change7.74%
50-Day Moving Average1.84
200-Day Moving Average2.15
Relative Strength Index (RSI)55.33
Average Volume (3m)106.08K
Important Dates
Whitehawk Therapeutics upcoming earnings date is Nov 5, 2025, Before Open (Confirmed).
Last Earnings DateAug 7, 2025
Next Earnings DateNov 5, 2025
Ex-Dividend Date―
Financial Position
Whitehawk Therapeutics as a current ratio of 3.59, with Debt / Equity ratio of 0.00%
Current Ratio3.59
Quick Ratio3.28
Debt to Market Cap0.00
Net Debt to EBITDA0.43
Interest Coverage Ratio-438.04
Taxes
In the past 12 months, Whitehawk Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Whitehawk Therapeutics EV to EBITDA ratio is -0.89, with an EV/FCF ratio of -0.94.
EV to Sales2.22
EV to EBITDA-0.89
EV to Free Cash Flow-0.94
EV to Operating Cash Flow-0.97
Balance Sheet
Whitehawk Therapeutics has $177.20M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$177.20M billion.
Cash & Marketable Securities$177.20M
Total Debt$0.00
Net Cash-$177.20M
Net Cash Per Share-$3.76
Tangible Book Value Per Share$1.94
Margins
Gross margin is -23.62%, with operating margin of -259.62%, and net profit margin of -245.13%.
Gross Margin-23.62%
Operating Margin-259.62%
Pretax Margin-245.13%
Net Profit Margin-245.13%
EBITDA Margin-248.73%
EBIT Margin-249.47%
Analyst Forecast
The average price target for Whitehawk Therapeutics is $2.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$2.00
Price Target Upside10.50% Upside
Analyst ConsensusHold
Analyst Count3
Revenue Growth Forecast-9.33%
EPS Growth Forecast97.60%